NeuroBo Starts Phase 2a Clinical Trial Evaluating DA-1241 for Treatment of NASH

 NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced dosing of the first patient in its two-part, Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, for the treatment of nonalcoholic steatohepatitis (NASH), at The Pinnacle Edinberg/South Texas Research Institute in Edinburg, Texas, under the supervision of Principal Investigator, Dr. David Ramirez.

https://www.biospace.com/article/releases/neurobo-pharmaceuticals-doses-first-patient-in-its-phase-2a-clinical-trial-evaluating-da-1241-for-the-treatment-of-nash/